AbCellera Narrows Q3 Loss to $40.8M as ABCL635 Phase 2 Data Drives $200M Raise
ABCL has more than doubled off its 52-week low of $2.745.
Summary
AbCellera reported Q3 2026 revenue of $10.6 million versus $9.0 million a year ago, while net loss narrowed to $40.8 million from $57.1 million as R&D and SG&A spending both fell. The quarter's centerpiece was positive top-line Phase 2 data for ABCL635 in menopausal vasomotor symptoms, which the company says supports late-stage development starting in 2027 and expansion into hormone-suppression-induced VMS in breast and prostate cancer patients. On the strength of that data AbCellera completed the $200 million offering priced in August at $9.75, lifting total available liquidity to over $890 million against a $4.05 billion market cap. The subsequent Phase 1 readout for ABCL575 met all endpoints but the company does not plan to advance it past Phase 1, and partner-led programs slipped to 34 from 44 at year-end 2025. Watch the 2027 late-stage ABCL635 trial start and the IND-enabling work on ABCL386, ABCL688, ABCL992, ABCL385 and ABCL646.
At the time of this announcement, ABCL was trading at $12.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $2.75 to $15.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.